Abelson interactor 1 splice isoform-L plays an anti-oncogenic role in colorectal carcinoma through interactions with WAVE2 and full-length Abelson interactor 1

Figure 2 The proportion of Abelson interactor 1 splice isoform-L is significantly decreased in colon cancer tissues and cell lines compared to other Abelson interactor 1 splice isoforms. A: Expression of endogenous Abelson interactor 1 splice isoform-L (ABI1-SiL) in colorectal carcinoma cells. M, 100 bp DNA Marker; 1, ABI1-Tv1 positive Ctrl (278 bp); 2, ABI1-SiL positive control (101 bp, orange arrow); 3, CRL-1541; 4, HCT-116; 5, HT-29; 6, LoVo; 7, LS174T; 8, SW480; 9, SW620; 10, negative control; B: ABI1-Tv1, ABI1-SiL, or a mixture of ABI1-Tv1 and ABI1-SiL were used as templates to confirm the feasibility of the ABI1-SiL quantitative polymerase chain reaction assay using the ABI1-U2 (lanes 1, 3, 5, 7, and 9) and ABI1-U1 primers (lanes 2, 4, 6, 8, and 10); C: ABI1-U1- (lanes 2 and 5) and ABI1-U2-specific (lanes 3 and 6) polymerase chain reaction products amplified from cDNA from CRL-1541 (lanes 1-3) and HCT116 (lanes 4-6) cells. Lanes 1 and 4 contain GAPDH (glyceraldehyde-3-phosphate dehydrogenase); D: The ratio of ABI1-SiL relative to all other ABI1 isoforms was significantly decreased in colorectal carcinoma cells compared with control CRL-1541 cells; E: The ratio of ABI1-SiL relative to other ABI1 isoforms was significantly decreased in 66.7% (16/24) of all tested colorectal tissues compared with adjacent tissues. M: Maker; ABI1: Abelson interactor 1; Aj: Adjacent; Ca: Cancer.